Navigation Links
Kosan in Medical Technology

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... HAYWARD, Calif., June 3 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...emedications and ease of pharmacist preparation. kosan anticipates conducting additional studies with tan...s trastuzumab will continue on study per protocol. kosan does not plan to enroll additional patients in thi...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

... HAYWARD, Calif., May 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...of the University of Pennsylvania. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...AYWARD, Calif., April 16 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...all of the leukemia models tested. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...AYWARD, Calif., April 14 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...disease in many additional tumors. About Kosan kosan Biosciences is a biotechnology company advancing t... in a Phase 1 trial. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...HAYWARD, Calif., Jan. 15 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...t cancer represents a major market opportunity for kosan that we intend to pursue," said Robert G. Johnson,...hree weeks out of four weeks in repeated cycles. kosan is also testing alvespimycin delivered orally in a...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

... HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...d to be progression-free survival. About Kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

...HAYWARD, Calif., Oct. 23 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...pending on data from expanded dose cohorts. About kosan kosan Biosciences is a biotechnology company advancing t...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

...AYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) presente...with reduced doses (one patient remains on study). kosan plans to continue to enroll patients at the 80 mg/...tion. Expanded Phase 1 Trial Includes Paclitaxel kosan has expanded the Phase 1 trial to add weekly dosin...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

...HAYWARD, Calif., Sept. 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...e FDA's Special Protocol Assessment (SPA) process, kosan and the FDA have reached agreement on overall prot...-agent bortezomib. The Special Protocol Assessment kosan has completed applies to the TIME-1 trial. TIME-2,...

Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma

... HAYWARD, Calif., Aug. 2 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...ed primarily by the patient's level of M protein. kosan anticipates that the pivotal TIME-1 trial will beg...ion of cytotoxic proteins, leading to cell death. kosan reported data from a Phase 1b trial of tanespimyci...

Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease

... HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- kosan Biosciences Incorporated (Nasdaq: KOSN ) today an...PF-04548043 in healthy subjects. In December 2006, kosan and Pfizer established a worldwide license agreeme... and this may improve the symptoms of GERD. About kosan ...

Kosan Announces Data Presentations at Upcoming AACR Annual Meeting

...cer therapeutics kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...ization agreement. For additional information on kosan Biosciences, please visit the company's website at...

Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR

...erval can lead to ventricular arrhythmia). About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR

...ent and duration of tumor regression was curative. kosan is currently advancing KOS-1803 through later-stag...nt in the area of cancer. In early 2007, Roche and kosan announced the decision to advance KOS-1584 into Ph...rch (AACR), being held in Los Angeles, CA. About kosan ...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...durability of action and a wide therapeutic index. kosan anticipates becoming the first company to advance ...r into clinical development. "We believe that kosan has established an industry-leading position in NE...ent potentially novel anticancer agents. About kosan ...

Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO

...s (with continued BRAF mutation analysis). About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO

...nd patients treated with bortezomib alone. About kosan kosan Biosciences is a biotechnology company advancing t...heat shock protein 90) inhibitors and epothilones. kosan is leveraging its proprietary discovery platform t...

Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO

...-small cell lung cancers and sarcomas. Roche and kosan plan to advance KOS-1584/R1645 into Phase 2 trials...ty with established chemotherapy regimens. About kosan kosan Biosciences is a biotechnology company advancing t...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...ans to add paclitaxel (Taxol(R)) to the regimen. kosan plans to initiate a Phase 2 study of alvespimycin ...b. This trial will be conducted in Eastern Europe. kosan anticipates that regulatory filings to support ini...clinical trial will be completed by mid-year 2007. kosan plans to initiate a larger, international Phase 2/...
Other Tags
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
(Date:12/20/2014)... 2014 DePuy Pinnacle hip lawsuits ... of the artificial hip system was defectively designed ... courts, Bernstein Liebhard LLP reports. According to an ... Court on December 2nd, counsel in 10 DePuy ... plaintiffs on November 19, 2014, with depositions to ...
(Date:12/20/2014)... (HealthDay News) -- The holidays can be anything but ... fresh trees, scented candles and other allergy triggers. ... that have been packed away in dank basements or ... asthma patients," Dr. Rachna Shah, an affiliate faculty member ... in Loyola news release. Shah, who is also ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... New York (PRWEB) December 20, 2014 ... continue to move forward in U.S. courts, Bernstein ... study which suggests that children treated with the ... hormone linked to breast development and lactation. The ... at 34 children and adolescents who began treatment ...
(Date:12/20/2014)... The aftermath of the November 24th hack ... only in Hollywood, but worldwide. As reported in ... of that attack are starting a finger-pointing game which could ... But they are not the only ones affected, regular employees ... some embarrassing times ahead, agents and lawyers could be in ...
Breaking Medicine News(10 mins):Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5
Other Contents